CAMX Stock Overview
A biopharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 6/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Camurus AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 646.50 |
| 52 Week High | SEK 714.50 |
| 52 Week Low | SEK 279.20 |
| Beta | 0.89 |
| 11 Month Change | 8.38% |
| 3 Month Change | 30.29% |
| 1 Year Change | 122.62% |
| 33 Year Change | 256.39% |
| 5 Year Change | 750.66% |
| Change since IPO | 879.55% |
Recent News & Updates
Earnings Miss: Camurus AB (publ) Missed EPS By 11% And Analysts Are Revising Their Forecasts
Jul 19
We Ran A Stock Scan For Earnings Growth And Camurus (STO:CAMX) Passed With Ease
Jul 12Recent updates
Earnings Miss: Camurus AB (publ) Missed EPS By 11% And Analysts Are Revising Their Forecasts
Jul 19We Ran A Stock Scan For Earnings Growth And Camurus (STO:CAMX) Passed With Ease
Jul 12Camurus AB (publ)'s (STO:CAMX) CEO Will Probably Have Their Compensation Approved By Shareholders
May 02Investors Appear Satisfied With Camurus AB (publ)'s (STO:CAMX) Prospects
Apr 19Camurus' (STO:CAMX) Strong Earnings Are Of Good Quality
Feb 22With EPS Growth And More, Camurus (STO:CAMX) Makes An Interesting Case
Feb 17Camurus AB (publ) (STO:CAMX) Investors Are Less Pessimistic Than Expected
Dec 20Need To Know: Analysts Are Much More Bullish On Camurus AB (publ) (STO:CAMX) Revenues
Nov 11We Think Camurus' (STO:CAMX) Profit Is Only A Baseline For What They Can Achieve
Feb 22We Think Camurus (STO:CAMX) Can Easily Afford To Drive Business Growth
Apr 30We Think Camurus (STO:CAMX) Can Easily Afford To Drive Business Growth
Dec 09Shareholder Returns
| CAMX | SE Pharmaceuticals | SE Market | |
|---|---|---|---|
| 7D | -3.6% | -2.4% | -4.3% |
| 1Y | 122.6% | 74.8% | 12.6% |
Return vs Industry: CAMX exceeded the Swedish Pharmaceuticals industry which returned 74.8% over the past year.
Return vs Market: CAMX exceeded the Swedish Market which returned 12.6% over the past year.
Price Volatility
| CAMX volatility | |
|---|---|
| CAMX Average Weekly Movement | 6.1% |
| Pharmaceuticals Industry Average Movement | 10.8% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in SE Market | 12.2% |
| 10% least volatile stocks in SE Market | 3.4% |
Stable Share Price: CAMX's share price has been volatile over the past 3 months.
Volatility Over Time: CAMX's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1991 | 213 | Fredrik Tiberg | www.camurus.com |
Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, and internationally. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence and chronic pain and Brixadi to treat opioid use disorder. Its products pipeline also includes CAM2038 for the treatment of chronic pain; CAM2029, which is in phase III clinical trials for the treatment of acromegaly and neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 that is in phase I clinical trial for the treatment of pulmonary arterial hypertension, as well as in Phase II clinical trial to treat Raynaud’s phenomenon.
Camurus AB (publ) Fundamentals Summary
| CAMX fundamental statistics | |
|---|---|
| Market cap | SEK 37.91b |
| Earnings (TTM) | SEK 223.25m |
| Revenue (TTM) | SEK 1.59b |
169.8x
P/E Ratio23.8x
P/S RatioIs CAMX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CAMX income statement (TTM) | |
|---|---|
| Revenue | SEK 1.59b |
| Cost of Revenue | SEK 127.24m |
| Gross Profit | SEK 1.47b |
| Other Expenses | SEK 1.24b |
| Earnings | SEK 223.25m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 07, 2024
| Earnings per share (EPS) | 3.81 |
| Gross Margin | 92.01% |
| Net Profit Margin | 14.01% |
| Debt/Equity Ratio | 0% |
How did CAMX perform over the long term?
See historical performance and comparison